Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials
Nicola Potter(European Bioinformatics Institute), Richard Dillon(King's College London), Jelena Jovanović(Centre de Recherche Jean Pierre Aubert), Ian Thomas(Cardiff University), Abin Thomas(Cardiff University), William Villiers(King's College London), Adam Ivey(The Alfred Hospital), Sean Johnson(Cardiff University), Amanda Gilkes(Cardiff University), Asim Khwaja(The Royal Free Hospital), Sylvie Freeman(University of Birmingham), Manohursingh Runglall(King's College London), Nigel H. Russell(Nottingham University Hospitals NHS Trust), Anju Kanda(King's College London), Robert K. Hills(Cancer Research UK Clinical Trials Unit), Jad Othman(King's College London), Joanna Canham(Cardiff University), Mary Frances McMullin(Queen's University Belfast), Ulrik Malthe Overgaard(Copenhagen University Hospital), Ellen Solomon(King's College London), Alan Burnett(University of Glasgow), Jamie Cavenagh(St Bartholomew's Hospital), Steven Knapper(Cardiff University)
Cited by 9
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750